These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22238978)

  • 1. [Neurotensin-like oligopeptides as potential antipsychotics: effect on dopamine system].
    Kost NV; Meshavkin VK; Batishcheva EIu; Sokolov OIu; Andreeva LA; Miasoedov NF
    Eksp Klin Farmakol; 2011; 74(10):3-6. PubMed ID: 22238978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.
    Mechanic JA; Sutton JE; Berson AE; Wu X; Kwan J; Schreiber R; Pang Z; Button DC
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):466-75. PubMed ID: 19223157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical neuroleptic-like behavioral effects of neurotensin.
    Jolicoeur FB; Gagné MA; Rivest R; Drumheller A; St-Pierre S
    Brain Res Bull; 1993; 32(5):487-91. PubMed ID: 8106129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 12-chloroscoulerine enantiomers on animal behavior to dopamine receptors.
    Chen LJ; Zhou QT; Dong ZJ; Yu LP; Jin GZ
    Zhongguo Yao Li Xue Bao; 1999 Oct; 20(10):884-8. PubMed ID: 11270985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
    Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
    Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dextromethorphan on dopamine dependent behaviours in rats.
    Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
    Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
    Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
    J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two distinctive apomorphine-induced phenotypes in the Roman high- and low-avoidance rats.
    Giménez-Llort L; Cañete T; Guitart-Masip M; Fernández-Teruel A; Tobeña A
    Physiol Behav; 2005 Nov; 86(4):458-66. PubMed ID: 16154604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin-like peptides as potential antipsychotics: modulation of the serotonin system.
    Kost NV; Meshavkin VK; Khashaba EY; Sokolov OY; Voevodina ME; Zolotarev YA; Andreeva LA; Myasoedov NF
    Bull Exp Biol Med; 2014 Oct; 157(6):738-41. PubMed ID: 25339589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.
    Zuo J; Liu Z; Ouyang X; Liu H; Hao Y; Xu L; Lu XH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):387-97. PubMed ID: 17935847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
    Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of apomorphine-, physostigmine- and pilocarpine-induced yawning after long-term treatment with neuroleptic or cholinergic agents.
    Ushijima I; Noda Y; Mizuki Y; Yamada M
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):180-8. PubMed ID: 6150689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of the dopamine-blocking and m-choline-blocking components in the antiapomorphine action of neuroleptics].
    Zharkovskiĭ AM; Langel IuL; Chereshka KS; Zharkovskaia TA
    Biull Eksp Biol Med; 1987 Mar; 103(3):317-9. PubMed ID: 2881585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.